CYSTOGRAFIN ® DILUTE Diatrizoate Meglumine Injection USP 18%

Manufacturer
BRACCO DIAGNOSTICS INC | PATHEON ITALIA SPA | Justesa Imagen, S.A.U
Effective date
2025-11-23
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
7
Source
full-release
Hydrated at
2026-05-31 21:47:57

Label at a glance#

ProductCystografin Dilute
Active ingredientdiatrizoate meglumine
Label structure11 sections

Dosage and administration

Preparation of the patient: Appropriate preparation is desirable for optimal results. A laxative the night before the examination and a low residue diet the day before the procedure are recommended. Dosage: The dose for retrograde use in cystography and voiding cystourethrography ranges from 25 to 300 mL depending on the age of the patient and the degree of bladder irritability; amounts greater than 300 mL may be ...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

For retrograde cystourethrography

Not intended for intravascular injection

DESCRIPTION

DESCRIPTION SECTION

Cystografin Dilute (Diatrizoate Meglumine Injection USP 18%) is a radiopaque contrast agent supplied as a sterile, aqueous solution. Each mL provides 180 mg diatrizoate meglumine with 0.4 mg edetate disodium as a sequestering agent. Each mL of solution also contains approximately 85 mg organically bound iodine. At the time of manufacture, the air in the container is replaced by nitrogen.

INDICATION

INDICATIONS & USAGE SECTION

Cystografin Dilute is indicated for retrograde cystourethrography.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

This preparation is contraindicated in patients with a hypersensitivity to salts of diatrizoic acid.

WARNINGS

WARNINGS SECTION

Severe sensitivity reactions are more likely to occur in patients with a personaI or family history of bronchial asthma, significant allergies, or previous reactions to contrast agents.

A history of sensitivity to iodine per se or to other contrast agents is not an absolute contraindication to the use of diatrizoate meglumine, but calls for extreme caution in administration.

PRECAUTIONS

PRECAUTIONS SECTION

Safe and effective use of this preparation depends upon proper dosage, correct technique, adequate precautions, and readiness for emergencies.

Retrograde cystourethrography should be performed with caution in patients with a known active infectious process of the urinary tract.

Sterile technique should be employed in administration. During administration, care should be taken to avoid excessive pressure, rapid or acute distention of the bladder, and trauma.

Contrast agents may interfere with some chemical determinations made on urine specimens; therefore, urine should be collected before administration of the contrast medium or two or more days afterwards.

Pregnancy–Teratogenic Effects:

TERATOGENIC EFFECTS SECTION

Animal reproduction studies have not been conducted with diatrizoate meglumine injection. It is also not known whether diatrizoate meglumine injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Cystografin Dilute should be administered to a pregnant woman only if clearly needed.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Retrograde genitourinary procedures may cause such complications as hematuria, perforation of the urethra or bladder, introduction of infection into the genitourinary tract, and oliguria or anuria.

If intravasation of this drug occurs, the reactions which may be associated with intravenous administration may possibly be encountered. Hypersensitivity or anaphylactoid reactions may occur. Severe reactions may be manifested by edema of the face and glottis, respiratory distress, convulsions or shock; such reactions may prove fatal unless promptly controlled by such emergency measures as maintenance of a clear airway and immediate use of oxygen and resuscitative drugs.

Endocrine: Thyroid function tests indicative of hypothyroidism or transient thyroid suppression have been uncommonly reported following iodinated contrast media administration to adult and pediatric patients, including infants. Some patients were treated for hypothyroidism.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

SPL UNCLASSIFIED SECTION

Preparation of the patient: Appropriate preparation is desirable for optimal results. A laxative the night before the examination and a low residue diet the day before the procedure are recommended.

SPL UNCLASSIFIED SECTION

Dosage: The dose for retrograde use in cystography and voiding cystourethrography ranges from 25 to 300 mL depending on the age of the patient and the degree of bladder irritability; amounts greater than 300 mL may be used if the bladder capacity allows. Best results are obtained when the bladder is filled with the contrast agent.

SPL UNCLASSIFIED SECTION

Administration: After sterile catheterization, the bladder should be filled to capacity with Cystografin Dilute using a suitable sterile administration set. Care should be taken to avoid using excessive pressure. The presence of bladder discomfort or reflux and/or spontaneous voiding usually indicates that the bladder is full.

SPL UNCLASSIFIED SECTION

Radiography: The commonly employed radiographic techniques should be used. A scout film is recommended before the contrast agent is administered.

HOW SUPPLIED

HOW SUPPLIED SECTION

Cystografin Dilute (Diatrizoate Meglumine Injection USP 18%) is available in packages of ten 300 mL bottIes (NDC 0270-1410-30).

Storage

STORAGE AND HANDLING SECTION

Store at 20-25°C (68-77°F) [See USP]; protect from light.

SPL UNCLASSIFIED SECTION

Revised June 2024

Rx only

Manufactured for
Bracco Diagnostics Inc.
Princeton, NJ 08540

by Patheon Italia S.p.A.
03013 Ferentino (Italy)

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

CYSTOGRAFIN DILUTE 18% - 300ML
NDC 0270-1410-30

CYSTOGRAFIN DILUTE 300ML
CYSTOGRAFIN DILUTE 300ML

CYSTOGRAFIN DILUTE 18% 1 Box - 10 BTL x 300ML
NDC 0270-1410-30

CYSTOGRAFIN DILUTE 1 Box 10 BTL 300ML
CYSTOGRAFIN DILUTE 1 Box 10 BTL 300ML

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
DIATRIZOIC ACID Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

Product Linked Resources#

Resource, Code type, Value table
ResourceCode typeValueEquivalent identifiersSource image
Data codeCode 1280270141030CYSTOGRAFIN DILUTE 300ML.jpg

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
a8f1679b-19b1-407c-9ee3-d33055bee6fcProduct name220250731

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
0270-1410-30Cystografin Dilute10 in 1 PACKAGEINJECTION, SOLUTION107
0270-1410-30Cystografin Dilute300 mL in 1 BOTTLEINJECTION, SOLUTION3007

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
0270-1410-30ML - Milliliter0270-14106032a8be-b1a8-4686-b595-ca4b181e450412013-02-13

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
diatrizoate meglumineACTIVE INGREDIENT3X9MR4N98U5
diatrizoic acidACTIVE MOIETY5UVC90J1LK5
edetate disodiumINACTIVE INGREDIENT7FLD91C86K5

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 4 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
0270-14100270-1410-30

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 2 matching rows.

Name, UNII, Kind table
NameUNIIKind
diatrizoate meglumine3X9MR4N98UACTIB
edetate disodium7FLD91C86KIACT

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 1 · 6 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
edetate disodiumEDETATE DISODIUM7FLD91C86KINJECTION, SOLUTION / INTRAMUSCULAR4 mgExact identifier — unii+dosage form
6 equally ranked IID candidates
edetate disodiumEDETATE DISODIUM7FLD91C86KINJECTION, SOLUTION / INTRAVENOUS7 mgExact identifier — unii+dosage form
6 equally ranked IID candidates
edetate disodiumEDETATE DISODIUM7FLD91C86KINJECTION, SOLUTION / SUBCUTANEOUS2 mgExact identifier — unii+dosage form
6 equally ranked IID candidates
edetate disodiumEDETATE DISODIUM7FLD91C86KINJECTION, SOLUTION / SUBCUTANEOUS2 mgExact identifier — unii+dosage form
6 equally ranked IID candidates
edetate disodiumEDETATE DISODIUM7FLD91C86KINJECTION, SOLUTION / INTRAMUSCULAR4 mgExact identifier — unii+dosage form
6 equally ranked IID candidates
edetate disodiumEDETATE DISODIUM7FLD91C86KINJECTION, SOLUTION / INTRAVENOUS7 mgExact identifier — unii+dosage form
6 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 44.

Orange Book products#

Current product rows page 1 of 1 · 10 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N010040-001RENOGRAFIN-76DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM66%;10%INJECTABLE / INJECTIONRLD, Approved before 1982
N010040-006RENOGRAFIN-60DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM52%;8%INJECTABLE / INJECTIONApproved before 1982
N010040-012RENO-DIPDIATRIZOATE MEGLUMINE30%INJECTABLE / INJECTIONApproved before 1982
N010040-016RENO-60DIATRIZOATE MEGLUMINE60%INJECTABLE / INJECTIONApproved before 1982
N010040-017DIATRIZOATE MEGLUMINEDIATRIZOATE MEGLUMINE76%INJECTABLE / INJECTIONApproved before 1982
N010040-018CYSTOGRAFINDIATRIZOATE MEGLUMINE30%SOLUTION / URETHRALRLD, Approved before 1982
N010040-019RENOVIST IIDIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM28.5%;29.1%INJECTABLE / INJECTIONApproved before 1982
N010040-020RENOVISTDIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM34.3%;35%INJECTABLE / INJECTIONApproved before 1982
N010040-021RENO-30DIATRIZOATE MEGLUMINE30%SOLUTION / URETERALApproved before 1982
N010040-022CYSTOGRAFIN DILUTEDIATRIZOATE MEGLUMINE18%SOLUTION / URETHRALRLD1982-11-09

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 11 · 440 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-10-15 13:18:302026-09N010040-001RENOGRAFIN-7666%;10%INJECTABLE / INJECTIONRLD, Approved before 1982c2088c7a36db…
2026-10-15 13:18:302026-09N010040-006RENOGRAFIN-6052%;8%INJECTABLE / INJECTIONApproved before 1982c2088c7a36db…
2026-10-15 13:18:302026-09N010040-012RENO-DIP30%INJECTABLE / INJECTIONApproved before 1982c2088c7a36db…
2026-10-15 13:18:302026-09N010040-016RENO-6060%INJECTABLE / INJECTIONApproved before 1982c2088c7a36db…
2026-10-15 13:18:302026-09N010040-017DIATRIZOATE MEGLUMINE76%INJECTABLE / INJECTIONApproved before 1982c2088c7a36db…
2026-10-15 13:18:302026-09N010040-018CYSTOGRAFIN30%SOLUTION / URETHRALRLD, Approved before 1982c2088c7a36db…
2026-10-15 13:18:302026-09N010040-019RENOVIST II28.5%;29.1%INJECTABLE / INJECTIONApproved before 1982c2088c7a36db…
2026-10-15 13:18:302026-09N010040-020RENOVIST34.3%;35%INJECTABLE / INJECTIONApproved before 1982c2088c7a36db…
2026-10-15 13:18:302026-09N010040-021RENO-3030%SOLUTION / URETERALApproved before 1982c2088c7a36db…
2026-10-15 13:18:302026-09N010040-022CYSTOGRAFIN DILUTE18%SOLUTION / URETHRALRLD1982-11-09c2088c7a36db…
2026-09-14 22:38:342026-08N010040-001RENOGRAFIN-7666%;10%INJECTABLE / INJECTIONRLD, Approved before 198284e616aacf4f…
2026-09-14 22:38:342026-08N010040-006RENOGRAFIN-6052%;8%INJECTABLE / INJECTIONApproved before 198284e616aacf4f…
2026-09-14 22:38:342026-08N010040-012RENO-DIP30%INJECTABLE / INJECTIONApproved before 198284e616aacf4f…
2026-09-14 22:38:342026-08N010040-016RENO-6060%INJECTABLE / INJECTIONApproved before 198284e616aacf4f…
2026-09-14 22:38:342026-08N010040-017DIATRIZOATE MEGLUMINE76%INJECTABLE / INJECTIONApproved before 198284e616aacf4f…
2026-09-14 22:38:342026-08N010040-018CYSTOGRAFIN30%SOLUTION / URETHRALRLD, Approved before 198284e616aacf4f…
2026-09-14 22:38:342026-08N010040-019RENOVIST II28.5%;29.1%INJECTABLE / INJECTIONApproved before 198284e616aacf4f…
2026-09-14 22:38:342026-08N010040-020RENOVIST34.3%;35%INJECTABLE / INJECTIONApproved before 198284e616aacf4f…
2026-09-14 22:38:342026-08N010040-021RENO-3030%SOLUTION / URETERALApproved before 198284e616aacf4f…
2026-09-14 22:38:342026-08N010040-022CYSTOGRAFIN DILUTE18%SOLUTION / URETHRALRLD1982-11-0984e616aacf4f…
2026-08-18 06:07:402026-07N010040-001RENOGRAFIN-7666%;10%INJECTABLE / INJECTIONRLD, Approved before 1982caaa826d4ba7…
2026-08-18 06:07:402026-07N010040-006RENOGRAFIN-6052%;8%INJECTABLE / INJECTIONApproved before 1982caaa826d4ba7…
2026-08-18 06:07:402026-07N010040-012RENO-DIP30%INJECTABLE / INJECTIONApproved before 1982caaa826d4ba7…
2026-08-18 06:07:402026-07N010040-016RENO-6060%INJECTABLE / INJECTIONApproved before 1982caaa826d4ba7…
2026-08-18 06:07:402026-07N010040-017DIATRIZOATE MEGLUMINE76%INJECTABLE / INJECTIONApproved before 1982caaa826d4ba7…
2026-08-18 06:07:402026-07N010040-018CYSTOGRAFIN30%SOLUTION / URETHRALRLD, Approved before 1982caaa826d4ba7…
2026-08-18 06:07:402026-07N010040-019RENOVIST II28.5%;29.1%INJECTABLE / INJECTIONApproved before 1982caaa826d4ba7…
2026-08-18 06:07:402026-07N010040-020RENOVIST34.3%;35%INJECTABLE / INJECTIONApproved before 1982caaa826d4ba7…
2026-08-18 06:07:402026-07N010040-021RENO-3030%SOLUTION / URETERALApproved before 1982caaa826d4ba7…
2026-08-18 06:07:402026-07N010040-022CYSTOGRAFIN DILUTE18%SOLUTION / URETHRALRLD1982-11-09caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N010040-001RENOGRAFIN-7666%;10%INJECTABLE / INJECTIONRLD, Approved before 1982011fe1cb6892…
2026-02-19 14:30 UTC2026-02N010040-006RENOGRAFIN-6052%;8%INJECTABLE / INJECTIONApproved before 1982011fe1cb6892…
2026-02-19 14:30 UTC2026-02N010040-012RENO-DIP30%INJECTABLE / INJECTIONApproved before 1982011fe1cb6892…
2026-02-19 14:30 UTC2026-02N010040-016RENO-6060%INJECTABLE / INJECTIONApproved before 1982011fe1cb6892…
2026-02-19 14:30 UTC2026-02N010040-017DIATRIZOATE MEGLUMINE76%INJECTABLE / INJECTIONApproved before 1982011fe1cb6892…
2026-02-19 14:30 UTC2026-02N010040-018CYSTOGRAFIN30%SOLUTION / URETHRALRLD, Approved before 1982011fe1cb6892…
2026-02-19 14:30 UTC2026-02N010040-019RENOVIST II28.5%;29.1%INJECTABLE / INJECTIONApproved before 1982011fe1cb6892…
2026-02-19 14:30 UTC2026-02N010040-020RENOVIST34.3%;35%INJECTABLE / INJECTIONApproved before 1982011fe1cb6892…
2026-02-19 14:30 UTC2026-02N010040-021RENO-3030%SOLUTION / URETERALApproved before 1982011fe1cb6892…
2026-02-19 14:30 UTC2026-02N010040-022CYSTOGRAFIN DILUTE18%SOLUTION / URETHRALRLD1982-11-09011fe1cb6892…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Cystografin DiluteDIATRIZOATE MEGLUMINEBRACCO DIAGNOSTICS INCe56882fa-4a30-43b1-bb6b-f7d4a4101c4e2025-11-23Warnings, Adverse reactionsExact identifier
ndc (package): 0270-1410-30
ndc (product): 0270-1410
ndc11 (package): 00270141030
spl id: 2f934688-ef2a-f0c7-0551-629d917b8358
spl set id: e56882fa-4a30-43b1-bb6b-f7d4a4101c4e

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.